Mechanisms of action of EGFR tyrosine kinase receptor incorporated in extracellular vesicles

Mechanisms of action of EGFR tyrosine kinase receptor incorporated in extracellular vesicles

EGFR and some of the cognate ligands extensively traffic in extracellular vesicles (EVs) from different biogenesis pathways. EGFR belongs to a family of four homologous tyrosine kinase receptors (TKRs). This family are one of the major drivers of cancer and is involved in several of the most frequen...

ver descrição completa

Detalhes bibliográficos
Principais autores:	Zanetti-Domingues, LC, Martin-Fernandez, ML, Huber, V
Formato:	Journal article
Idioma:	English
Publicado em:	MDPI 2020

Registros relacionados

Mechanisms of Action of EGFR Tyrosine Kinase Receptor Incorporated in Extracellular Vesicles
por: Laura C. Zanetti-Domingues, et al.
Publicado em: (2020-11-01)

Cooperation and interplay between EGFR signalling and extracellular vesicle biogenesis in cancer
por: Zanetti-Domingues, LC, et al.
Publicado em: (2020)

Cooperation and Interplay between EGFR Signalling and Extracellular Vesicle Biogenesis in Cancer
por: Laura C. Zanetti-Domingues, et al.
Publicado em: (2020-12-01)

Characterization of acquired receptor tyrosine–kinase fusions as mechanisms of resistance to EGFR tyrosine–kinase inhibitors
por: Xu H, et al.
Publicado em: (2019-07-01)

Extracellular Vesicles As Mediators of Resistance to EGFR-Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancer Preclinical Models
por: M. Pérez-Capó, et al.
Publicado em: (2023-11-01)

Mechanisms of resistance to EGFR tyrosine kinase inhibitors
por: Lihua Huang, et al.
Publicado em: (2015-09-01)

Depleting receptor tyrosine kinases EGFR and HER2 overcomes resistance to EGFR inhibitors in colorectal cancer
por: Lu Yang, et al.
Publicado em: (2022-06-01)

Radiation-Induced Tumor-Derived Extracellular Vesicles Combined with Tyrosine Kinase Inhibitors: An Effective and Safe Therapeutic Approach for Lung Adenocarcinoma with EGFR19Del
por: Yao Li, et al.
Publicado em: (2024-12-01)

HIV Activates the Tyrosine Kinase Hck to Secrete ADAM Protease-Containing Extracellular Vesicles
por: J.-H. Lee, et al.
Publicado em: (2018-02-01)

Discovery of novel dual inhibitors of receptor tyrosine kinases EGFR and IGF-1R
por: Cornelius Hempel, et al.
Publicado em: (2017-01-01)

Clinical activity of the EGFR tyrosine kinase inhibitor osimertinib in EGFR-mutant glioblastoma
por: Igor Makhlin, et al.
Publicado em: (2019-11-01)

An extracellular receptor tyrosine kinase motif orchestrating intracellular STAT activation
por: Katri Vaparanta, et al.
Publicado em: (2022-11-01)

Structural Insight and Development of EGFR Tyrosine Kinase Inhibitors
por: Tasia Amelia, et al.
Publicado em: (2022-01-01)

Extracellular vesicle-associated tyrosine kinase-like orphan receptors ROR1 and ROR2 promote breast cancer progression
por: Barnabas Irmer, et al.
Publicado em: (2023-07-01)

Receptor tyrosine kinases: Characterisation, mechanism of action and therapeutic interests for bone cancers
por: Aude I. Ségaliny, et al.
Publicado em: (2015-03-01)

Editorial: Discovery of EGFR tyrosine kinase inhibitors for cancer treatment
por: Panupong Mahalapbutr, et al.
Publicado em: (2024-02-01)

Extracellular Vesicles Act as Nano-Transporters of Tyrosine Kinase Inhibitors to Revert Iodine Avidity in Thyroid Cancer
por: Ramya Lakshmi Rajendran, et al.
Publicado em: (2021-02-01)

Moving the Needle Cautiously in Targeting One of the Most Often Acquired Receptor Tyrosine Fusion (RET Fusion) Resistance Mechanisms to EGFR Tyrosine Kinase Inhibitors
por: Shannon S. Zhang, MD, et al.
Publicado em: (2022-08-01)

Drug Tolerance to EGFR Tyrosine Kinase Inhibitors in Lung Cancers with <i>EGFR</i> Mutations
por: Kenichi Suda, et al.
Publicado em: (2021-06-01)

Immunotherapy strategies for EGFR-mutated advanced NSCLC after EGFR tyrosine-kinase inhibitors failure
por: Xingyuan Li, et al.
Publicado em: (2023-10-01)

Mechanisms of receptor tyrosine kinase activation in cancer
por: Zhenfang Du, et al.
Publicado em: (2018-02-01)

Crystal structure of the Sema-PSI extracellular domain of human RON receptor tyrosine kinase.
por: Kinlin L Chao, et al.
Publicado em: (2012-01-01)

Action Mechanisms of Small Extracellular Vesicles in Inflammaging
por: Rocío Mato-Basalo, et al.
Publicado em: (2022-04-01)

Osimertinib – effective treatment of NSCLC with activating EGFR mutations after progression on EGFR tyrosine kinase inhibitors
por: Marcin Skrzypski, et al.
Publicado em: (2017-09-01)

Primary Resistance to EGFR Tyrosine Kinase Inhibitors (TKIs): Contexts and Comparisons in EGFR-Mutated Lung Cancer
por: Keigo Kobayashi
Publicado em: (2023-12-01)

BIM mediates EGFR tyrosine kinase inhibitor-induced apoptosis in lung cancers with oncogenic EGFR mutations.
por: Daniel B Costa, et al.
Publicado em: (2007-10-01)

EGFR tyrosine kinase activity and Rab GTPases coordinate EGFR trafficking to regulate macrophage activation in sepsis
por: Xuedi Zhang, et al.
Publicado em: (2022-11-01)

Impact of MET alterations on targeted therapy with EGFR-tyrosine kinase inhibitors for EGFR-mutant lung cancer
por: Zhe Zhang, et al.
Publicado em: (2019-11-01)

Discovery of novel dual inhibitors of receptor tyrosine kinases EGFR and PDGFR-β related to anticancer drug resistance
por: Tim Fischer, et al.
Publicado em: (2018-01-01)

A preliminary results of integrated chemotherapy with EGFR receptor tyrosine kinase inhibitors in patients with non-small-cell-lung cancer harboring EGFR mutation
por: K. K. Laktionov, et al.
Publicado em: (2019-06-01)

miR-494 in Extracellular Vesicles as a Potent Biomarker of Chronic Myeloid Leukemia Treatment with Tyrosine Kinase Inhibitors
por: Tatsuki Shibuta, et al.
Publicado em: (2022-06-01)

Proteolytic Cleavage of Receptor Tyrosine Kinases
por: Hao Huang
Publicado em: (2021-04-01)

Receptor Tyrosine Kinases — Expanding Horizons
por: Sassan Hafizi
Publicado em: (2014-06-01)

Extracellular phosphorylation of a receptor tyrosine kinase controls synaptic localization of NMDA receptors and regulates pathological pain.
por: Kenji Hanamura, et al.
Publicado em: (2017-07-01)

Mechanisms of Activation of Receptor Tyrosine Kinases: Monomers or Dimers
por: Ichiro N. Maruyama
Publicado em: (2014-04-01)

In Vitro Activation and Inhibition of Recombinant EGFR Tyrosine Kinase Expressed in Escherichia coli
por: Jihene Elloumi-Mseddi, et al.
Publicado em: (2013-01-01)

Afatinib and Necitumumab in EGFR-Mutant NSCLC with Acquired Resistance to Tyrosine Kinase Inhibitors
por: Nathaniel J. Myall, MD, et al.
Publicado em: (2025-02-01)

ALGORITHMS FOR MANAGEMENT OF PATIENTS WITH ADVERSE EVENTS ON THERAPY WITH TYROSINE KINASE INHIBITORS EGFR
por: D. D. SAKAEVA
Publicado em: (2017-06-01)

Remodeling of tumor microenvironments by EGFR tyrosine kinase inhibitors in EGFR-mutant non-small cell lung cancer
por: Soomin Kim, et al.
Publicado em: (2025-02-01)

The Prediction Of Epidermal Growth Factor Receptor Mutation And Prognosis Of EGFR Tyrosine Kinase Inhibitor By Serum Ferritin In Advanced NSCLC
por: Wu Z, et al.
Publicado em: (2019-10-01)